Rare Disease New Drug Stocks Surge by 3 Trillion Won in One Day

Shares of rare-disease drug developer InSMED Inc. (NASDAQ: INSM) closed at $143.61 on the most recent trading day on Nasdaq, up 7.77%.
Its market capitalization climbed to about $31 billion (roughly KRW 43 trillion), adding approximately $2.6 billion (in the high KRW 3 trillion range) in a single day.
Trading volume reached 1,406,208 shares, a notably strong level.

InSMED recently announced it will discontinue development of brensocatib for moderate to severe hidradenitis suppurativa after its Phase 2b CEDAR trial failed to meet both primary and secondary efficacy endpoints.

The company is set to report first-quarter results on May 7 (U.S. time). Analysts anticipate narrower losses and about $300 million in revenue, highlighting the growth potential of brensocatib alongside InSMED’s existing products.

Headquartered in Bridgewater, New Jersey, InSMED is a biotech firm specializing in rare pulmonary diseases. Its respiratory rare-disease pipeline includes Arikayce for refractory MAC lung disease and Brensupri (brensocatib) for non-cystic fibrosis bronchiectasis. Brensocatib, marketed as Brensupri, has been approved in the U.S. and Europe, making it a cornerstone of InSMED’s growth story.